Bone Marrow Transplant is Beneficial for Some Rare Childhood Diseases >> Hematopoietic Stem-Cell Transplantation in the Pediatric Population - Research Review - Final | AHRQ Effective Health Care Program

open here please:

Hematopoietic Stem-Cell Transplantation in the Pediatric Population - Research Review - Final AHRQ Effective Health Care Program

Research Review - Final – Feb. 1, 2012

Hematopoietic Stem-Cell Transplantation in the Pediatric Population

Formats

• View PDF 3.8 MB  
• Help with Viewers, Players, and Plug-ins

This final research review is available in PDF (3.8 MB) format only. Persons using assistive technology may not be able to fully access information in this file. For assistance, please contact us.


Bone Marrow Transplant is Beneficial for Some Rare Childhood Diseases
Bone marrow transplant (hematopoietic stem-cell transplant (HSCT)) can be an effective treatment for children with Wolman’s disease, a rare inherited metabolic disorder that typically causes death in infancy, and Faber’s disease Type 2/3, a rare fatal inherited metabolic disorder, according to a new research review from AHRQ’s Effective Health Care Program. However, insufficient evidence on the benefits or harms of HSCT versus other standard treatments exists for most other rare pediatric conditions.. These findings can be found in the new research review, Hematopoietic Stem Cell Transplantation in the Pediatric Population, and the future research needs are identified in an accompanying report, Future Research Needs for Hematopoietic Stem Cell Transplantation in the Pediatric Population.

Research Review - Final – Feb. 1, 2012

Future Research Needs for Hematopoietic Stem-Cell Transplantation in the Pediatric Population

Formats

• View PDF 1.5 MB  
• Help with Viewers, Players, and Plug-ins

This final research review is available in PDF (1.5 MB) format only. Persons using assistive technology may not be able to fully access information in this file. For assistance, please contact us.

Now open for comment.